Workflow
虚拟资产交易平台
icon
Search documents
九方智投控股(09636.HK)拟战略投资香港持牌虚拟资产交易平台EX.IO 加快推进海外数字资产业务布局与市场拓展
Ge Long Hui· 2025-09-23 10:29
Core Viewpoint - JF SmartTrade, a wholly-owned subsidiary of NineFang Smart Investment Holdings, has entered into a share subscription agreement with EX.IO, a virtual asset trading platform, to enhance its overseas digital asset business strategy [1] Group 1: Company Overview - NineFang Smart Investment Holdings is focusing on expanding its digital asset business through strategic investments [1] - EX.IO, established in 2023 in the Cayman Islands, operates primarily in Hong Kong and has received a virtual asset trading platform license from the Securities and Futures Commission in December 2024 [1] Group 2: Strategic Intent - The investment in EX.IO is aimed at leveraging its trading resources and Web3 technology to accelerate the company's overseas digital asset business development [1] - The board believes that this subscription aligns with the company's overall strategic planning and the intended use of the raised funds [1] Group 3: Market Positioning - The funds raised from the subscription will be strategically invested in the digital asset exchange to foster the development of an on-chain financial ecosystem [1] - This move is seen as a core component of the company's overseas strategy, enhancing its capabilities in on-chain financial services and supporting business diversification and sustainable growth [1]
中金:维持连连数字跑赢行业评级 上调目标价至15.8港元
Zhi Tong Cai Jing· 2025-08-28 02:03
Core Viewpoint - The report from CICC indicates a significant increase in the Total Payment Volume (TPV) for Lianlian Digital, leading to an upward revision of revenue forecasts for 2025 and 2026 by 2% to 1.65 billion and 2.02 billion HKD respectively, while maintaining adjusted profit estimates unchanged [1] Group 1: Financial Performance - In 1H25, Lianlian Digital's revenue increased by 27% year-on-year to 780 million HKD, with net profit turning positive at 151 million HKD compared to a net loss of 350 million HKD in 1H24, largely due to over 1.6 billion HKD in gains from the sale of part of its stake in LianTong [2] - The TPV for 1H25 rose by 32% year-on-year to 2.1 trillion HKD, outpacing the revenue growth of 27% [3] - Gross profit for 1H25 increased by 25% year-on-year to 410 million HKD, maintaining a high gross margin of 52% [4] Group 2: Business Segments - Global payment TPV surged by 94% year-on-year to 198.5 billion HKD, although the overall fee rate declined to 24 basis points due to higher growth in lower-fee service trade and B2B sectors [3] - Domestic payment TPV grew by 28% year-on-year to 1.9 trillion HKD, with a stable fee rate of 1.1 basis points [3] - Value-added services revenue increased by 34% year-on-year to 90 million HKD, primarily driven by contributions from virtual card services [3] Group 3: Strategic Initiatives - The company plans to allocate 50% of the funds raised from placements to enhance blockchain technology applications in cross-border payments, aiming to improve efficiency and security [7] - The company has received approval for the VATP virtual asset trading platform license, which is expected to expand its service capabilities in cross-border payments [7] - The company anticipates steady growth in TPV and payment revenue, projecting a near 700 million HKD in regular operating profit for 2025 [6]
港股异动 | 维信金科(02003)绩后涨近7% 中期净利同比增长79.5% 战略投资EXIO集团加码新兴技术应用
智通财经网· 2025-08-26 01:36
Group 1 - The core viewpoint of the news is that Weixin Jinke (02003) has shown strong financial performance in the first half of 2025, with total revenue reaching 2.5 billion RMB, a year-on-year increase of 43.8%, and a net profit of 216 million RMB, up 79.5% year-on-year [1] - The company plans to distribute an interim dividend of 0.05 HKD per share to reward shareholders for their long-term trust and support [1] - Weixin Jinke has actively adjusted its business strategy to enhance risk control and operational efficiency, aiming to build a safe and compliant digital financial ecosystem [1] Group 2 - Weixin Jinke is expanding its business in emerging technology fields by strategically investing in EXIO Group, one of the first 11 virtual asset trading platforms approved by the Hong Kong Securities and Futures Commission [2] - This investment aims to bridge traditional finance and the Web 3.0 ecosystem, helping Weixin Jinke explore the collaborative value between traditional financial systems and emerging digital asset domains [2] - The company is focused on driving innovation in complex scenarios and establishing higher industry standards in asset security and user experience [2]
龙虎榜复盘 | RWA概念今日反弹大涨,脑机接口资金活跃
Xuan Gu Bao· 2025-08-14 10:55
Group 1: Stock Market Activity - Today, 35 stocks were listed on the institutional trading list, with 16 stocks seeing net purchases and 19 stocks experiencing net sales [1] - The top three stocks with the highest net purchases by institutions were: Innovation Medical (128 million), Youfang Technology (76.31 million), and Nanmo Biology (56.58 million) [1][2] Group 2: Company Developments - Youfang Technology has announced plans to engage in financing leasing to support its cloud computing services, driven by the growing demand for computing power in the artificial intelligence sector [2] - The company has previously focused on providing cloud infrastructure products to meet customer needs for storage, computing, and transportation [2] Group 3: Brain-Computer Interface Industry - The brain-computer interface product developed by Botuo Bio has entered the clinical trial phase, showing significant recovery effects in the first treated depression patient, with plans to start medical device registration in 2026 [4] - The Chinese government has issued policies to promote innovation in the brain-computer interface industry, with expectations for breakthroughs in key technologies by 2027 [4] - McKinsey predicts that the global market for medical applications of brain-computer interfaces could reach $40 billion by 2030 and $145 billion by 2040, with specific segments for central nervous system disease treatment and emotional assessment [4]